Danville, Pa.-based Geisinger Health System and pharmaceutical company Boehringer Ingelheim joined forces to create a predictive model to improve health outcomes for Type 2 diabetes patients, the companies announced Sept. 25.
The project, rolled out through Boehringer Ingelheim's diabetes alliance with pharmaceutical company Eli Lilly and Co., will develop a risk model to predict the likelihood of three health outcomes associated with Type 2 diabetes: cardiovascular death, kidney failure and hospitalization for heart failure.
The researchers will develop the model using de-identified data from Geisinger's EHR. The ultimate goal is to create a model that informs personalized treatments for patients with Type 2 diabetes.
"We hope the knowledge gained from this predictive model can help healthcare providers better target their treatment recommendations for people with Type 2 diabetes and, as a result, lower their risk for these serious diabetes-related consequences," said Brent Williams, PhD, a research investigator at the Geisinger Center for Health Research.
More articles on data analytics & precision medicine:
8 things to know about gene-editing tech CRISPR
Louisiana State U, Moffitt Cancer Center partner to address racial disparities in precision medicine
Survey: Healthcare execs name data analytics, population health among top challenges for 2018